PMID- 32066847
OWN - NLM
STAT- MEDLINE
DCOM- 20201116
LR  - 20210216
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Feb 17
TI  - The effects of a multispecies synbiotic on microbiome-related side effects of 
      long-term proton pump inhibitor use: A pilot study.
PG  - 2723
LID - 10.1038/s41598-020-59550-x [doi]
LID - 2723
AB  - Side effects of proton pump inhibitors (PPI) can be linked to the changes in the 
      intestinal microbiome that occur during therapy, especially in long-term users. 
      Therefore, the microbiome might also be a key player in the reduction of PPI side 
      effects. We tested the effects of a three-month intervention with a multispecies 
      synbiotic on intestinal inflammation, gut barrier function, microbiome 
      composition, routine laboratory parameters and quality of life in patients with 
      long-term PPI therapy. Thirty-six patients received a daily dose of a 
      multispecies synbiotic for three months and were clinically observed without 
      intervention for another three months. After intervention 17% of patients reached 
      normal calprotectin levels; the overall reduction did not reach statistical 
      significance (-18.8 ng/mg; 95%CI: -50.5; 12.9, p = 0.2). Elevated zonulin levels 
      could be significantly reduced (-46.3 ng/mg; 95%CI: -71.4; -21.2; p < 0.001). The 
      abundance of Stomatobaculum in the microbiome was reduced and Bacillus increased 
      during the intervention. Furthermore, albumin, alkaline phosphatase and 
      thrombocyte count were significantly increased and aspartate transaminase was 
      significantly decreased during intervention. Gastrointestinal quality of life 
      showed significant improvements. In conclusion, microbiome-related side effects 
      of long-term PPI use can be substantially reduced by synbiotic intervention. 
      Further studies are warranted to optimize dosage and duration of the 
      intervention.
FAU - Horvath, Angela
AU  - Horvath A
AUID- ORCID: 0000-0001-7279-0628
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria. angela.horvath@medunigraz.at.
AD  - Center for Biomarker Research in Medicine (CBmed), Graz, Austria. 
      angela.horvath@medunigraz.at.
FAU - Leber, Bettina
AU  - Leber B
AD  - Division of Transplantation Surgery, Medical University of Graz, Graz, Austria.
FAU - Feldbacher, Nicole
AU  - Feldbacher N
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
AD  - Center for Biomarker Research in Medicine (CBmed), Graz, Austria.
FAU - Steinwender, Markus
AU  - Steinwender M
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
FAU - Komarova, Irina
AU  - Komarova I
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
FAU - Rainer, Florian
AU  - Rainer F
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
FAU - Blesl, Andreas
AU  - Blesl A
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
FAU - Stadlbauer, Vanessa
AU  - Stadlbauer V
AUID- ORCID: 0000-0001-5508-8271
AD  - Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, 
      Austria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200217
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Haptoglobins)
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 0 (Prebiotics)
RN  - 0 (Protein Precursors)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (zonulin)
RN  - D8TST4O562 (Pantoprazole)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - N3PA6559FT (Esomeprazole)
RN  - Stomatobaculum longum
SB  - IM
MH  - Aged
MH  - Alkaline Phosphatase/genetics/metabolism
MH  - Anti-Ulcer Agents/administration & dosage/*adverse effects
MH  - Aspartate Aminotransferases/genetics/metabolism
MH  - Bacillus/classification/isolation & purification
MH  - Clostridiales/classification/isolation & purification
MH  - Dysbiosis/chemically induced/physiopathology/*prevention & control
MH  - Esomeprazole/administration & dosage/adverse effects
MH  - Female
MH  - Gastroesophageal Reflux/microbiology/physiopathology/*therapy
MH  - Gastrointestinal Microbiome/physiology
MH  - Gene Expression Regulation
MH  - Haptoglobins/genetics/metabolism
MH  - Humans
MH  - Lactobacillus/classification/isolation & purification
MH  - Lactococcus/classification/isolation & purification
MH  - Leukocyte L1 Antigen Complex/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole/administration & dosage/adverse effects
MH  - Peptic Ulcer/microbiology/physiopathology/*therapy
MH  - Pilot Projects
MH  - Prebiotics/*administration & dosage
MH  - Probiotics/*therapeutic use
MH  - Protein Precursors/genetics/metabolism
MH  - Proton Pump Inhibitors/administration & dosage/*adverse effects
MH  - Quality of Life
PMC - PMC7026433
COIS- A.H. received travel grants from Winclove Probiotics, outside the submitted work; 
      V.S. received personal fees from Institut Allergosan, personal fees from Winclove 
      Probiotics, grants from Fresenius Kabi Austria and personal fees from Ferring, 
      outside the submitted work; B.L., N.F., M.S., I.K., F.R., A.B. have nothing to 
      disclose. All authors have read the journal's policy on conflicts of interest.
EDAT- 2020/02/19 06:00
MHDA- 2020/11/18 06:00
PMCR- 2020/02/17
CRDT- 2020/02/19 06:00
PHST- 2019/05/28 00:00 [received]
PHST- 2020/01/30 00:00 [accepted]
PHST- 2020/02/19 06:00 [entrez]
PHST- 2020/02/19 06:00 [pubmed]
PHST- 2020/11/18 06:00 [medline]
PHST- 2020/02/17 00:00 [pmc-release]
AID - 10.1038/s41598-020-59550-x [pii]
AID - 59550 [pii]
AID - 10.1038/s41598-020-59550-x [doi]
PST - epublish
SO  - Sci Rep. 2020 Feb 17;10(1):2723. doi: 10.1038/s41598-020-59550-x.